Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax

The Bcl-2 family inhibitors venetoclax and navitoclax demonstrated potent antitumor activity in chronic lymphocytic leukemia patients, notably in reducing marrow load and adenopathy. Subsequent trials with venetoclax have been initiated in non-Hodgkin's lymphoma and multiple myeloma patients. T...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Pharmacol Res Perspect
Päätekijät: Ackler, Scott, Oleksijew, Anatol, Chen, Jun, Chyla, Brenda J, Clarin, Jerry, Foster, Kelly, McGonigal, Thomas, Mishra, Sasmita, Schlessinger, Sally, Smith, Morey L, Tahir, Stephen K, Leverson, Joel D, Souers, Andrew J, Boghaert, Erwin R, Hickson, Jonathan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Ltd 2015
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4618648/
https://ncbi.nlm.nih.gov/pubmed/26516589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.178
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia